Double‐blind study of oral γ‐vinyl GABA in the treatment of dystonia

Abstract
Six patients with different forms of dystonia were treated with γ-vinyl GABA, a specific enzyme-activated inhibitor of GABA-trans-aminase, in a double-blind, placebo-controlled crossover study, γ-Vinyl GABA therapy, 2 g daily for 2 weeks, was compared with placebo by weekly assessments. There were no consistent changes in three evaluation scores. Agents that augment CNS GABA are unlikely to benefit patients with generalized dystonia.